Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, adding new casdatifan arms to the ROSETTA RCC-208 study.

The kidney cancer trial expansion comes after a mixed period for Bristol-Myers Squibb, with the share price at $56.24, a year to date share price return of 5.2%, and a 1 year total shareholder return of 21.35%. This suggests improving momentum despite a weaker 90 day share price return that declined 5.81%.

If you are watching how big pharma is leaning into new therapies like kidney cancer combinations, it can also be worth scanning for opportunities in healthcare focused AI stocks through the 39 healthcare AI stocks

With Bristol-Myers Squibb stock trading at $56.24, offering a 4.5% dividend yield, a value score of 4, and an indicated 53% intrinsic discount, investors have to ask whether this represents a genuine mispricing or if the market is already factoring in future growth.

Most Popular Narrative: 10.7% Undervalued

The most followed narrative pegs Bristol-Myers Squibb stock at a fair value of $62.96 versus the last close at $56.24, framing a modest undervaluation rooted in detailed assumptions about revenue, margins and required return.

Analysts are assuming Bristol-Myers Squibb's revenue will decrease by 6.2% annually over the next 3 years.

Analysts assume that profit margins will increase from 15.0% today to 21.5% in 3 years time.

Want to understand why lower revenue paired with higher margins can still support a higher fair value for Bristol-Myers Squibb? The narrative leans on a detailed path for earnings, a richer future earnings multiple, and a specific discount rate that together do most of the heavy lifting in this valuation story.

Result: Fair Value of $62.96 (UNDERVALUED)

However, Bristol-Myers Squibb also faces real pressure from upcoming patent expiries on key drugs and the possibility that newer launches and pipeline assets underperform expectations.

Another View: What Bristol-Myers Squibb’s P/E Is Signaling

While the most popular Bristol-Myers Squibb narrative leans on detailed earnings and margin forecasts, the current P/E of 15.8x tells a slightly different story. It is a bit higher than the US pharmaceuticals industry at 15.1x, yet below peers at 22.3x and under the fair ratio of 18.7x. This combination points to both valuation risk and potential opportunity, depending on which reference point you consider more relevant. The key question is which signal matters most for you right now.

Next Steps

Given the mix of optimism and caution around Bristol-Myers Squibb, it helps to move quickly and review the data firsthand by comparing both the risks and rewards via the 3 key rewards and 3 important warning signs.

Looking For More Investment Ideas Beyond Bristol-Myers Squibb?

If Bristol-Myers Squibb has your attention, this is the moment to broaden your watchlist so you do not miss other compelling opportunities across the market.

• Spot potential bargains early by scanning screener containing 20 high quality undiscovered gems that pair solid fundamentals with lower market attention.
• Strengthen your portfolio's foundation by reviewing companies in the solid balance sheet and fundamentals stocks screener (48 results) that prioritize financial resilience.
• Target dependable income streams by assessing high yield opportunities in the 9 dividend fortresses before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.